Ingestible Sensor and Wearable Sensor
OtherThis digital health offering passively acquires and records medication-taking and habits of daily living.
NCT Number: NCT02553512
The purpose of this study is to demonstrate the use of a digital health offering in the management of persistent hypertension during chronic anti-hypertensive treatment.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
In patients with persistent essential systolic hypertension,who are undergoing assessment of their current pharmaceutical burden for blood pressure control, a digital health offering is used (1) to provide automatic and passive electronic documentation of medication adherence and patterns of medication taking, (2) to assist providers in distinguishing inadequate medication adherence or pharmacologic unresponsiveness as the root cause for persistent hypertension, and (3) to inform management decisions (dose adjustment, medication addition or substitution, adherence counseling, referral to a hypertension specialist).
Participating patients wear an adhesive Wearable Sensor ("Patch") continuously with replacement after one week, and ingest an inert tablet ("Pill") containing an Ingestible Sensor daily whenever they take their prescribed anti-hypertensive drugs.
The Patch automatically detects and records the dates and times of each "Pill" ingestion, daily step count, sleep duration and sleep interruptions, and the circadian pattern of rest and activity. After completion of each Patch's use, the recorded data are downloaded and incorporated into a report that includes blood pressures that are obtained at the time of clinic visits at the beginning and after 2 weeks of service use.
The final report is generated automatically and provided electronically to practitioners for review with their patient. The information that is obtained is incorporated by practitioners in advising next steps for blood pressure management.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This digital health offering passively acquires and records medication-taking and habits of daily living.
Time frame: 2 weeks
Percent timing adherence is determined by the number of ingestion sensors detected by the wearable monitor, divided by the total number of ingestion sensors prescribed, for the 2 week-time frame.
Time frame: 2 weeks
Percent scheduling adherence is determined by the number of ingestion sensors detected within a ± 2-hour time window around the prescribed dosing period, divided by the number of ingestion sensors detected by the wearable sensor during that dosing period, over the 2-week time frame.
Time frame: 2 weeks
Percentage of participants
Time frame: 2 weeks
Decrease in systolic and diastolic blood pressure (measured in mm Hg) after 2 weeks when compared to baseline
Time frame: 4 weeks
Summary of provider actions following review of final report with patient (dose or medication change, adherence counseling, referral to a hypertension specialist)
Proteus Digital Health, Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07704697
Cardiovascular Diseases, Essential Hypertension
Beijing, Beijing Municipality, China
View Trial DetailsNCT07704684
Cardiovascular Diseases, Essential Hypertension
Beijing, Beijing Municipality, China
View Trial DetailsNCT07700875
Cardiovascular Diseases, Essential Hypertension
Jinan, Shangdong, China
View Trial DetailsNCT05503953
Cardiovascular Diseases, Essential Hypertension
Seoul, South Korea
View Trial Details